Tumor Metabolism as a Regulator of Tumor–Host Interactions in the B-Cell Lymphoma Microenvironment—Fueling Progression and Novel Brakes for Therapy

Beielstein, Anna C; Pallasch, Christian P.

doi:10.3390/ijms20174158

Cited by 14 publications

(9 citation statements)

References 207 publications

(269 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many biological processes regulated by the CSF- and brain biopsy-derived CNS DLBCL-specific set of miRs were found to be related to cellular metabolism. This is in line with the previously postulated tumor metabolism-dependent shaping of the B-NHL microenvironment, which influence tumor progression [ 74 ].…”

Section: Discussionsupporting

confidence: 91%

A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors

et al. 2021

View full text Add to dashboard Cite

The diagnosis of primary central nervous system (CNS) lymphoma, which is predominantly of the diffuse large B-cell lymphoma type (CNS DLBCL), is challenging. MicroRNAs (miRs) are gene expression-regulating non-coding RNAs that are potential biomarkers. We aimed to distinguish miR expression patterns differentiating CNS DLBCL and non-malignant CNS diseases with tumor presentation (n-ML). Next generation sequencing-based miR profiling of cerebrospinal fluids (CSFs) and brain tumors was performed. Sample source-specific (CSF vs. brain tumor) miR patterns were revealed. Even so, a set of 17 miRs differentiating CNS DLBCL from n-ML, no matter if assessed in CSF or in a tumor, was identified. Along with the results of pathway analyses, this suggests their pathogenic role in CNS DLBCL. A combination of just four of those miRs (miR-16-5p, miR-21-5p, miR-92a-3p, and miR-423-5p), assessed in CSFs, discriminated CNS DLBCL from n-ML samples with 100% specificity and 67.0% sensitivity. Analyses of paired CSF-tumor samples from patients with CNS DLBCL showed significantly lower CSF levels of miR-26a, and higher CSF levels of miR-15a-5p, miR-15b-5p, miR-19a-3p, miR-106b-3p, miR-221-3p, and miR-423-5p. Noteworthy, the same miRs belonged to the abovementioned set differentiating CNS DLBCL from non-malignant CNS diseases. Our results not only add to the basic knowledge, but also hold significant translational potential.

show abstract

Section: Discussionsupporting

confidence: 91%

A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Finally, the PI3K/AKT/mTOR signaling also plays an important role in the different non-neoplastic cells that are present in the tumor microenvironment, for example regulating the proliferation and migration of endothelial cells, the M1/M2 polarization of macrophages, and the activation and/or differentiation of T cells [56][57][58][59][60][61][62].…”

Section: Deregulation Of the Signaling In Lymphomamentioning

confidence: 99%

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

Tarantelli

Lupia

Stathis

et al. 2020

IJMS

View full text Add to dashboard Cite

The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti-cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K/mTOR inhibitors as single agents and in combination in lymphomas. Clinical responses, including complete remissions (especially in follicular lymphoma patients), are also observed in the very few clinical studies performed in patients that are affected by relapsed/refractory lymphomas or chronic lymphocytic leukemia. In this review, we summarize the literature on dual PI3K/mTOR inhibitors focusing on the lymphoma setting, presenting both the three compounds still in clinical development and those with a clinical program stopped or put on hold.

show abstract

“…Multiple preclinical and clinical studies showed the anti-tumor activity of PI3Kδ inhibitors in patients affected by chronic lymphocytic leukemia (CLL), B- and T-cell lymphomas and these data have been extensively summarized elsewhere [ 3 , 4 , 5 , 6 , 7 , 8 ]. Importantly, PI3Ks are expressed not only in the cancer cells, but also in the non-neoplastic cells, in which PI3K inhibitors contribute to their pro- or anti-tumor effects, and they can be used to improve the response to immunomodulatory and immunotherapeutic agents [ 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ]. In this review article, we will discuss the effects of inhibiting PI3Kδ isoform on the immune system with a particular focus on the T-cell compartment.…”

Section: Introductionmentioning

confidence: 99%

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

Tarantelli

Argnani

Zinzani

et al. 2021

Cancers

View full text Add to dashboard Cite

The development of small molecules able to block specific or multiple isoforms of phosphoinositide 3-kinases (PI3K) has already been an active field of research for many years in the cancer field. PI3Kδ inhibitors are among the targeted agents most extensively studied for the treatment of lymphoma patients and PI3Kδ inhibitors are already approved by regulatory agencies. More recently, it became clear that the anti-tumor activity of PI3K inhibitors might not be due only to a direct effect on the cancer cells but it can also be mediated via inhibition of the kinases in non-neoplastic cells present in the tumor microenvironment. T-cells represent an important component of the tumor microenvironment and they comprise different subpopulations that can have both anti- and pro-tumor effects. In this review article, we discuss the effects that PI3Kδ inhibitors exert on the immune system with a particular focus on the T-cell compartment.

show abstract

Tumor Metabolism as a Regulator of Tumor–Host Interactions in the B-Cell Lymphoma Microenvironment—Fueling Progression and Novel Brakes for Therapy

Cited by 14 publications

References 207 publications

A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors

A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors

Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?

PI3Kδ Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients

Contact Info

Product

Resources

About